BDPT Company Profile and Key Details

BioAdaptives Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.04. This means the shares are trading below this model’s fair value.

Average 10-day trading volume of 12.66 million shares is below the 3-month average of 19.93 million, indicating normal recent market interest.

Our AI price prediction model suggests that BioAdaptives, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Valuation shows BioAdaptives, Inc. trading at a premium to the broader market with a P/E of -0.01.

The stock is currently mid-range between its 52-week high and low $0.00 and $0.07. With a market capitalization of about $16.81 thousand, BioAdaptives Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.19). Key stats such as the average daily volume over the past year has been around 20.61 million shares, in line with its 52-week average. Headquartered in Las Vegas, NV, BioAdaptives Inc. operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO James Keener, the company employs approximately 1 people and listed since June 01, 2016. BioAdaptives, Inc. is a research and development company that develops and markets nutraceutical and dietary supplement products for humans and animals.

BioAdaptives, Inc. trades at a P/E ratio of -0.01, slightly below the S&P 500 average, with a price-to-sales ratio of 0.66 and a price-to-book ratio of -0.01 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.06, also above market averages.